How to Screen Psychiatric History Before Considering Psychedelic Therapy
How should clinicians screen baseline psychiatric history when considering a patient for psychedelic therapy?
Patients seeking psychedelic therapy may report no prior psychiatric hospitalizations and still carry important psychosis vulnerability. This study suggests that screening should extend beyond hospitalization history to include outpatient psychotic and other psychiatric diagnoses, because baseline comorbidity materially changes how psychosis risk is interpreted.
-
Screen outpatient and inpatient psychosis history
Before considering psychedelic therapy, review the patient's full psychiatric history across care settings rather than relying only on prior psychiatric admissions. The article specifically concludes that screening should extend beyond hospitalization history because psychosis-related admissions represented only a subset of those with baseline psychotic disorders.
-
Identify baseline psychotic vulnerability first
Prioritize detection of any baseline psychotic disorder diagnosis because this was the clearest confounder of the crude hallucinogen-psychosis association. In adjusted analyses, baseline psychotic disorders and psychosis admissions remained important predictors of later psychosis, whereas hallucinogen-related admission itself did not retain an independent significant association with psychosis diagnosis.
-
Screen for mood and anxiety disorders as part of the baseline profile
Include mood and anxiety disorders in the pretherapy psychiatric review. The study modeled these baseline psychiatric conditions as relevant covariates because broader psychiatric comorbidity may predispose individuals both to hallucinogen-related care and to later psychosis-related outcomes.
-
Screen for co-occurring substance use disorders
Assess opioid, stimulant, cannabis, and alcohol use disorders during pretherapy evaluation. The hallucinogen-related cohort had substantial baseline substance-related comorbidity, and stimulant and opioid use disorders were among the strongest predictors of postindex psychosis in adjusted models.
-
Clarify whether substance use is likely polysubstance rather than isolated
Ask specifically about use of multiple substances over time and in the same setting. The study found that only about 10% of patients with hallucinogen-related admissions had no other nonhallucinogen substance-related admissions, supporting the expectation that polysubstance exposure is common.
-
Use caution when the patient's age overlaps usual psychosis onset
Interpret risk cautiously in younger adults whose age overlaps the common onset period for schizophrenia spectrum disorders. The study highlights that the hallucinogen-related cohort had a median age of 24 years, making it difficult to separate exposure effects from prodromal or emerging primary psychotic illness.
Clinical Considerations
- This article did not test a prospective clinical screening tool for psychedelic therapy candidates; it supports the content of screening rather than a validated clinic protocol.
- The findings come from administrative claims data in patients with substance-related admissions, not from therapeutic psychedelic treatment populations.
- Residual confounding may persist even after adjustment, so the study informs risk assessment but does not establish a definitive causal model for any individual patient.
Bottom Line
When considering psychedelic therapy, screen comprehensively for outpatient and inpatient psychotic history plus co-occurring psychiatric and substance use disorders, because baseline vulnerability matters more than hallucinogen exposure alone in estimating psychosis risk.
